Novel avian single-chain fragment variable (scFv) targets dietary gluten and related natural grain prolamins, toxic entities of celiac disease

BMC Biotechnology

Valerie Stadlmann¹  Hanna Harant³  Irina Korschineck³  Marcela Hermann²  Florian Forster¹  Albert Missbichler¹ 

[1] Sciotec Diagnostics Technologies GmbH, Tulln, Austria

[2] Department of Medical Biochemistry, Division of Molecular Genetics, Medical University of Vienna, Vienna, Austria

[3] Ingenetix GmbH, Vienna, Austria

关键词: scFv;    Prolamins;    Dietary gluten;    Gliadin;    Wheat;    Celiac disease treatment;    Celiac disease;   

Others  :  1234797
DOI  :  10.1186/s12896-015-0223-z

 received in 2015-07-16, accepted in 2015-11-10,  发布年份 2015

【 摘 要 】

Background

Celiac disease (CD) is a chronic, small intestinal inflammatory disease mediated by dietary gluten and related prolamins. The only current therapeutic option is maintenance of a strict life-long gluten-free diet, which implies substantial burden for CD patients. Different treatment regimes might be feasible, including masking of toxic celiac peptides with blocking antibodies or fragments thereof. The objective of this study was therefore to select and produce a recombinant avian single-chain fragment variable (scFv) directed against peptic-tryptic digested gliadin (PT-Gliadin) and related celiac toxic entities.

Results

Gluten-free raised chicken of same age were immunized with PT-Gliadin. Chicken splenic lymphocytes, selected with antigen-coated magnetic beads, served as RNA source for the generation of cDNA. Chicken V _Hand V _Lgenes were amplified from the cDNA by PCR to generate full-length scFv constructs consisting of V _Hand V _Lfragments joined by a linker sequence. ScFv constructs were ligated in a prokaryotic expression vector, which provides a C-terminal hexahistidine tag.

ScFvs from several bacterial clones were expressed in soluble form and crude cell lysates screened for binding to PT-Gliadin by ELISA. We identified an enriched scFv motif, which showed reactivity to PT-Gliadin. One selected scFv candidate was expressed and purified to homogeneity. Polyclonal anti-PT-Gliadin IgY, purified from egg yolk of immunized chicken, served as control. ScFv binds in a dose-dependent manner to PT-Gliadin, comparable to IgY. Furthermore, IgY competitively displaces scFv from PT-Gliadin and natural wheat flour digest, indicating a common epitope of scFv and IgY. ScFv was tested for reactivity to different gastric digested dietary grain flours. ScFv detects common and khorasan wheat comparably with binding affinities in the high nanomolar range, while rye is detected to a lesser extent. Notably, barley and cereals which are part of the gluten-free diet, like corn and rice, are not detected by scFv. Similarly, the pseudo-grain amaranth, used as gluten-free alternative, is not targeted by scFv. This data indicate that scFv specifically recognizes toxic cereal peptides relevant in CD.

Conclusion

ScFv can be of benefit for future CD treatment regimes.

【 授权许可】

   
2015 Stadlmann et al.

【 参考文献 】

• [1]Jabri B, Kasarda DD, Green PHR. Innate and adaptive immunity: the yin and yang of celiac disease. Immunol Rev. 2005; 206:219-31.
• [2]Jabri B, Sollid LM. Mechanisms of disease: immunopathogenesis of celiac disease. Nat Clin Pract Gastroenterol Hepatol. 2006; 3:516-25.
• [3]Green PHR, Cellier C. Celiac disease. N Engl J Med. 2007; 357:1731-43.
• [4]Paveley WF. From Aretaeus to Crosby: a history of coeliac disease. BMJ. 1988; 297:1646-9.
• [5]van Berge-Henegouwen GP, Mulder CJ. Pioneer in the gluten free diet: Willem-Karel Dicke 1905–1962, over 50 years of gluten free diet. Gut. 1993; 34:1473-5.
• [6]Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PHR et al.. The Oslo definitions for coeliac disease and related terms. Gut. 2013; 62:43-52.
• [7]Lähdeaho M, Kaukinen K, Laurila K, Vuotikka P, Koivurova O, Kärjä-Lahdensuu T et al.. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology. 2014; 146:1649-58.
• [8]Crowe SE. Management of celiac disease: beyond the gluten-free diet. Gastroenterology. 2014; 146:1594-6.
• [9]Paterson BM, Lammers KM, Arrieta MC, Fasano A, Meddings JB. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. 2007; 26:757-66.
• [10]Wieser H. Chemistry of gluten proteins. Food Microbiol. 2007; 24:115-9.
• [11]Capozzi A, Vincentini O, Gizzi P, Porzia A, Longo A, Felli C et al.. Modulatory effect of gliadin peptide 10-mer on epithelial intestinal CACO-2 cell inflammatory response. PLoS One. 2013; 8:e66561.
• [12]Thomas KE, Sapone A, Fasano A, Vogel SN. Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in Celiac disease. J Immunol. 2006; 176:2512-21.
• [13]Troncone R, Gianfrani C, Mazzarella G, Greco L, Guardiola J, Auricchio S et al.. Majority of gliadin-specific T-cell clones from celiac small intestinal mucosa produce interferon-gamma and interleukin-4. Dig Dis Sci. 1998; 43:156-61.
• [14]Schade R, Calzado EG, Sarmiento R, Chacana PA, Porankiewicz-Asplund J, Terzolo HR. Chicken egg yolk antibodies (IgY-technology): a review of progress in production and use in research and human and veterinary medicine. Altern Lab Anim. 2005; 33:129-54.
• [15]Polson A. Isolation of IgY from the yolks of eggs by a chloroform polyethylene glycol procedure. Immunol Invest. 1990; 19:253-8.
• [16]Hansen P, Scoble JA, Hanson B, Hoogenraad NJ. Isolation and purification of immunoglobulins from chicken eggs using thiophilic interaction chromatography. J Immunol Methods. 1998; 215:1-7.
• [17]Vega CG, Bok M, Vlasova AN, Chattha KS, Fernández FM, Wigdorovitz A et al.. IgY antibodies protect against human Rotavirus induced diarrhea in the neonatal gnotobiotic piglet disease model. PLoS One. 2012; 7:e42788.
• [18]Rahman S, Higo-Moriguchi K, Htun KW, Taniguchi K, Icatlo FC, Tsuji T et al.. Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus-associated diarrhea among pediatric patients. Vaccine. 2012; 30:4661-9.
• [19]Dias da Silva W, Tambourgi DV. IgY: a promising antibody for use in immunodiagnostic and in immunotherapy. Vet Immunol Immunopathol. 2010; 135:173-80.
• [20]Fu C, Huang H, Wang X, Liu Y, Wang Z, Cui S et al.. Preparation and evaluation of anti-SARS coronavirus IgY from yolks of immunized SPF chickens. J Virol Methods. 2006; 133:112-5.
• [21]Meenatchisundaram S, Shanmugam V, Anjali VM. Development of chicken egg yolk antibodies against streptococcus mitis - purification and neutralizing efficacy. J Basic Clin Pharm. 2011; 2:109-14.
• [22]Oliver C, Valenzuela K, Silva H, Haro RE, Cortés M, Sandoval R et al.. Effectiveness of egg yolk immunoglobulin (IgY) against the intracellular salmonid pathogen Piscirickettsia salmonis. J Appl Microbiol. 2015; 119:365-76.
• [23]Gujral N, Löbenberg R, Suresh M, Sunwoo H. In-vitro and in-vivo binding activity of chicken egg yolk immunoglobulin Y (IgY) against gliadin in food matrix. J Agric Food Chem. 2012; 60:3166-72.
• [24]de Ritis G, Occorsio P, Auricchio S, Gramenzi F, Morisi G, Silano V. Toxicity of wheat flour proteins and protein-derived peptides for in vitro developing intestine from rat fetus. Pediatr Res. 1979; 13:1255-61.
• [25]Whitlow M, Bell BA, Feng SL, Filpula D, Hardman KD, Hubert SL et al.. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng. 1993; 6:989-95.
• [26]Loomans EE, Roelen AJ, van Damme HS, Bloemers HP, Gribnau TC, Schielen WJ. Assessment of the functional affinity constant of monoclonal antibodies using an improved enzyme-linked immunosorbent assay. J Immunol Methods. 1995; 184:207-17.
• [27]Safdari Y, Farajnia S, Asgharzadeh M, Khalili M, Jaliani HZ. Affinity measurement of single chain antibodies: a mathematical method facilitated by statistical software SigmaPlot. Monoclon Antib Immunodiagn Immunother. 2014; 33:13-9.
• [28]Lionetti E, Gatti S, Pulvirenti A, Catassi C. Celiac disease from a global perspective. Best Pract Res Clin Gastroenterol. 2015; 29:365-79.
• [29]Hall NJ, Rubin G, Charnock A. Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. Aliment Pharmacol Ther. 2009; 30:315-30.
• [30]Midhagen G, Hallert C. High rate of gastrointestinal symptoms in celiac patients living on a gluten-free diet: controlled study. Am J Gastroenterol. 2003; 98:2023-6.
• [31]Bardella MT, Velio P, Cesana BM, Prampolini L, Casella G, Di Bella C et al.. Coeliac disease: a histological follow-up study. Histopathology. 2007; 50:465-71.
• [32]Lee SK, Lo W, Memeo L, Rotterdam H, Green PHR. Duodenal histology in patients with celiac disease after treatment with a gluten-free diet. Gastrointest Endosc. 2003; 57:187-91.
• [33]Šuligoj T, Gregorini A, Colomba M, Ellis HJ, Ciclitira PJ. Evaluation of the safety of ancient strains of wheat in coeliac disease reveals heterogeneous small intestinal T cell responses suggestive of coeliac toxicity. Clin Nutr. 2013; 32:1043-9.
• [34]Gregorini A, Colomba M, Ellis HJ, Ciclitira PJ. Immunogenicity characterization of two ancient wheat α-gliadin peptides related to coeliac disease. Nutrients. 2009; 1:276-90.
• [35]Comino I, Moreno ML, Real A, Rodríguez-Herrera A, Barro F, Sousa C. The gluten-free diet: testing alternative cereals tolerated by celiac patients. Nutrients. 2013; 5:4250-68.
• [36]Ellis HJ, Rosen-Bronson S, O’Reilly N, Ciclitira PJ. Measurement of gluten using a monoclonal antibody to a coeliac toxic peptide of A-gliadin. Gut. 1998; 43:190-5.
• [37]Sturgess R, Day P, Ellis HJ, Lundin KE, Gjertsen HA, Kontakou M et al.. Wheat peptide challenge in coeliac disease. Lancet. 1994; 343:758-61.
• [38]Morón B, Bethune MT, Comino I, Manyani H, Ferragud M, López MC et al.. Toward the assessment of food toxicity for celiac patients: characterization of monoclonal antibodies to a main immunogenic gluten peptide. PLoS One. 2008; 3:e2294.
• [39]Comino I, Real A, Gil-Humanes J, Pistón F, de Lorenzo L, Moreno ML et al.. Significant differences in coeliac immunotoxicity of barley varieties. Mol Nutr Food Res. 2012; 56:1697-707.
• [40]Ludvigsson JF, Bai JC, Biagi F, Card TR, Ciacci C, Ciclitira PJ et al.. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut. 2014; 63:1210-28.
• [41]Bergamo P, Maurano F, Mazzarella G, Iaquinto G, Vocca I, Rivelli AR et al.. Immunological evaluation of the alcohol-soluble protein fraction from gluten-free grains in relation to celiac disease. Mol Nutr Food Res. 2011; 55:1266-70.